Recruiting

CPVTCRD-4730 for Catecholaminergic Polymorphic Ventricular Tachycardia

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

CRD-4730

+ Placebo

Drug
Who is being recruted

Cardiac Conduction System Disease+6

+ Polymorphic Catecholaminergic Ventricular Tachycardia

+ Arrhythmias, Cardiac

From 18 to 99 Years
+16 Eligibility Criteria
See all eligibility criteria
How is the trial designed

Treatment Study

Placebo-ControlledPhase 2
Interventional
Study Start: December 2025
See protocol details

Summary

Principal SponsorCardurion Pharmaceuticals, Inc.
Study ContactJason Homsy, MD, Ph.D.
Last updated: February 7, 2026
Sourced from a government-validated database.Claim as a partner

Study start date: December 1, 2025

Actual date on which the first participant was enrolled.

This study is focused on evaluating a new medication, CRD-4730, for individuals with a heart condition called Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT). CPVT can cause irregular heartbeats, which can be dangerous. The study aims to assess how safe and well-tolerated CRD-4730 is, as well as how it behaves in the body and how it affects the heart condition. The research is important because finding effective treatments for CPVT can help prevent life-threatening heart rhythm issues in those affected. Participants in the study will follow a structured plan where they will receive two different doses of CRD-4730 and a placebo at different times. The study is conducted in a way that neither the participants nor the researchers know who is receiving the actual medication or the placebo, ensuring unbiased results. This approach helps determine the safety and effectiveness of CRD-4730 by comparing its impact on the body to that of the placebo. The main focus will be on understanding the drug's safety and how it influences the heart condition.

Official TitleA Phase 2, Double-Blind, Repeat-Dose, Placebo-Controlled Crossover Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CRD-4730 In Participants With Catecholaminergic Polymorphic Ventricular Tachycardia
NCT06658899
Principal SponsorCardurion Pharmaceuticals, Inc.
Study ContactJason Homsy, MD, Ph.D.
Last updated: February 7, 2026
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

12 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 99 Years

Range of ages for which participants are eligible to join.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Cardiac Conduction System DiseasePolymorphic Catecholaminergic Ventricular TachycardiaArrhythmias, CardiacCardiovascular DiseasesHeart DiseasesPathologic ProcessesPathological Conditions, Signs and SymptomsTachycardiaTachycardia, Ventricular

Criteria

5 inclusion criteria required to participate
The participant has been on a stable dose of at least 1 antiarrhythmic medication (including beta blockers but not amiodarone) for 4 weeks prior to Screening, unless the participant has been unable to tolerate antiarrhythmic therapy previously.
Adheres to all contraceptive criteria.
The participant is male or female, ≥18 years of age and of legal adult age in accordance with local requirements.
The participant has a confirmed CPVT diagnosis, based on genetic screening for a pathogenic ryanodine receptor (RYR2) mutation and a clinical phenotype consistent with CPVT at Screening. Previous CPVT genetic testing documented in medical history is acceptable if confirmed by the Investigator and documented in the study source records.
Show More Criteria
11 exclusion criteria prevent from participating
The participant has clinically significant structural heart disease, diagnosis of heart failure, or clinically significant coronary artery disease.
The participant has a clinically significant abnormal ECG not explained by the diagnosis of CPVT at Screening or clinically significant abnormal intervals, such as prolonged QT.
The participant has a history of a myocardial infarction, cerebrovascular accident, or transient ischemic attack within 3 months of Screening.
The participant undergoes implantable cardioverter-defibrillator (ICD) implantation or has sympathetic nerve denervation within 3 months of Screening.
Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

3 intervention groups are designated in this study

33.333% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental
CRD-4730 Dose 1 Tablet

Group II

Experimental
CRD 4730 Dose 2 Tablet

Group III

Placebo
Placebo tablet to match CRD-4730

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 8 locations

Recruiting

Cardurion Investigative Site

San Francisco, United StatesOpen Cardurion Investigative Site in Google Maps
Recruiting

Cardurion Investigative Site

Morrisville, United States
Recruiting

Cardurion Investigative Site

Houston, United States
Recruiting

Cardurion Investigative Site

Madison, United States
Recruiting
8 Study Centers